Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SNDX
Strong SellSinkerSyndax Pharmaceuticals, Inc. · Healthcare · United States · $1.7B · Avg Vol: $26M/d
COMPANY DESCRIPTION
Syndax Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing innovative therapies for cancer. Its pipeline includes differentiated small molecules and biologics targeting critical pathways in tumor biology and immune response, such as menin inhibition and CD73 blockade. Syndax's strong focus on unmet needs in difficult-to-treat cancers, coupled with its robust clinical development programs, positions it as a specialized player in the competitive oncology drug development landscape.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 23.7M | 172.4M | 627.8% | 252.3M | 316.1M | — | 83.4% |
| EPS | -2.46 | -2.98 | -3.72 | -3.29 | — | -2.51 | -1.93 | -0.82 | — |
| Shares | 68.1M | 84.8M | 85.7M | 87.4M | +28.3% | 89.3M | — | — | — |
| Debt | 1.2M | 1.6M | 345.7M | 345.4M | 567.6% | 589.4M | — | — | — |
| Equity | 467.4M | 554.2M | 288.1M | 64.6M | -48.3% | — | — | — | — |
| Op CF | -133.7M | -160.6M | -274.9M | -323.0M | — | -220.6M | — | — | — |
| Inv CF | -186.2M | 117.6M | -219.8M | 290.0M | — | — | — | — | — |
| Fin CF | 172.3M | 264.1M | 353.4M | 13.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SNDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals, Inc.(you) | $1.7B | 6 | Strong Sell |
| NTLA | Intellia Therapeutics, Inc. | $1.8B | 7 | Strong Sell |
| GENB | Generate Biomedicines, Inc. | $2.0B | 6 | Strong Sell |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 8 | Strong Sell |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.5B | 6 | Strong Sell |
| TYRA | Tyra Biosciences, Inc. | $1.5B | 8 | Strong Sell |
| LTGO | Latigo Biotherapeutics, Inc. | $1.5B | 8 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 11 | Strong Sell |
| KARD | Kardigan, Inc. | $1.9B | 11 | Strong Sell |
| AVLN | Avalyn Pharma Inc. | $1.5B | 10 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%